Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Short term Debt (2022 - 2025)

Inhibikase Therapeutics (IKT) has 4 years of Short term Debt data on record, last reported at $37944.0 in Q2 2025.

  • On a quarterly basis, Short term Debt fell 75.07% to $37944.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $37944.0, a 75.07% decrease, with the full-year FY2024 number at $110517.0, down 26.37% from a year prior.
  • Short term Debt reached $37944.0 in Q2 2025 per IKT's latest filing, down from $74772.0 in the prior quarter.
  • Over the last five years, Short term Debt for IKT hit a ceiling of $152224.0 in Q2 2024 and a floor of $37944.0 in Q2 2025.
  • A 4-year average of $129475.2 and a median of $146368.5 in 2022 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: increased 4.92% in 2023, then plummeted 75.07% in 2025.
  • Tracing IKT's Short term Debt over 4 years: stood at $145836.0 in 2022, then rose by 2.92% to $150095.0 in 2023, then fell by 26.37% to $110517.0 in 2024, then plummeted by 65.67% to $37944.0 in 2025.
  • Business Quant data shows Short term Debt for IKT at $37944.0 in Q2 2025, $74772.0 in Q1 2025, and $110517.0 in Q4 2024.